Oncology Product Articles & Analysis
19 news found
Dedicated to the research of new immunotherapeutic vaccines in oncology and prophylactic vaccines for contagious diseases, the aim of the joint Institut Pasteur – Oncovita laboratory is to design and develop vaccine candidates through to proof of concept in humans. ...
ByOncoVITA
Mulinacci added, “I look forward to working with the team at Araris to expand on its business development efforts as they further advance their oncology pipeline of next-generation antibody-drug conjugates (ADCs) into the clinic. ...
The company’s mission is to lead a revolution in oncology therapy by delivering its innovative and targeted intra-arterial (IA) delivery of chemotherapy directly to solid tumors. ...
ByxCures
Elacestrant demonstrated longer progression-free survival (PFS) vs SOC endocrine therapy with medians up to 8.6 months, positively associated with the duration of prior treatment with CDK4/6 inhibitors Elacestrant side effects were manageable and consistent with previously reported results Results demonstrate that elacestrant may have the potential to become a new standard of care as a ...
BillionToOne, Inc., a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, announces the launch of its first oncology liquid biopsy products, Northstar Select™ and Northstar Response™. The products are currently available for research use with select academic ...
Rajangam will be broadly responsible for leading the development and regulatory strategy to rapidly advance Senti Bio's off-the-shelf CAR-NK cell oncology programs into and through clinical development. Dr. Rajangam joins Senti Bio from Nkarta Therapeutics where, as chief medical officer, she was responsible for clinical development of CAR-NK cell therapies for ...
Its primary therapeutic areas of interest include oncology, neurology, urology and dermatology. Ingenew’s current research and development efforts are evaluating proprietary preparations and delivery systems designed to improve the clinical efficacy and reduce toxicity and side effects associated with standard of care. ...
As such Valeo Pharma Inc. is responsible for all medical and commercial activities for both products which are two innovative therapies approved by Health Canada for the treatment of asthma. About Valeo Pharma About Valeo Pharma Valeo Pharma is a pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus ...
With more than 8 years of proven in-market safety data internationally and a robust supply chain ensuring product availability, we expect Redesca to continue playing a major role in the achievement of our growth objectives”. ...
(CSE:VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, today announced that it has successfully entered into a Product Listing Agreement (“PLA”) with Alberta Minister of Health, for the listing and public reimbursement of Enerzair Breezhaler and Atectura Breezhaler, its two innovative asthma therapies, ...
PsiOxus is developing this agent as one of several products within its T-SIGn® portfolio of vectors that combine systemic delivery with localized production of powerful transgene payloads to allow the selective re-engineering of both primary and metastatic tumors. ...
Most recently, Microbiotica entered a landmark collaboration in immuno-oncology with Cancer Research UK and Cambridge University Hospitals to develop microbiome co-therapeutics and biomarkers for cancer patients receiving checkpoint inhibitor therapy. In addition, the Company has existing programs in IBD and immuno-oncology, and major partnerships with the ...
About PsiOxus PsiOxus is a clinical stage oncology company pioneering systemic immune oncology products that drive sustained reprogramming of the tumor microenvironment to overcome the central challenge of resistance to therapy. ...
Amanda Kay is a biopharmaceutical executive with broad experience and expertise - across strategy development, operating plan implementation, business development, commercialization, financial planning and analysis, and R&D operations - married to a passion for working with scientists to translate innovative drug platform technologies into products that address unmet ...
Biosceptre is developing anti-cancer therapies – in particular, targeted therapeutics and immune-oncology products targeting most types of cancers, with the goal of bringing novel treatments to patients suffering from a wide range of malignancies. ...
Biosceptre, a biopharmaceutical company developing targeted therapeutics and immune-oncology products, has acquired the exclusive rights to Carina Biotech’s nfP2X7-targeted CAR-T cells and associated intellectual property, which has shown encouraging cancer-killing capacity against a number of cancers in pre-clinical testing. ...
“The approval of this important Radiation Oncology product allows us to offer the benefits of positivesignal MR imaging when treating the hundreds of thousands of patients who receive radiotherapy each year.” He added, “With 510(k) clearance we’re ready to transfer the device to production and will announce commercial ...
Hyderabad, India, 17th January 2019: Aurobindo Pharma Limited (BSE: 524804 and NSE: AUROPHARMA) ("Aurobindo"), announces the signing of a definitive agreement to acquire a portfolio of seven branded oncology injectable products from Spectrum pharmaceuticals Inc. The acquisition also brings-in an experienced branded commercial infrastructure in the US. ...
The popularity of HDR has increased in recent years due to its effectiveness and convenience; and the majority of Radiation Oncology practices in the US are able to offer the technique. The precise positioning of HDR applicators and needles prior to treatment is critical for accurate delivery of therapy. ...